Resource use and costs associated with different states of breast cancer

被引:51
作者
Lidgren, Mathias
Wilking, Nils
Jonsson, Bengt
Rehnberg, Clas
机构
[1] Karolinska Inst, Med Management Ctr, SE-17177 Stockholm, Sweden
[2] Karolinska Inst, Dept Oncol, SE-17176 Stockholm, Sweden
[3] Stockholm Sch Econ, Dept Econ, SE-11383 Stockholm, Sweden
关键词
resources use; direct cost; indirect cost; informal care cost; breast cancer;
D O I
10.1017/S0266462307070328
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives: This study investigated the direct medical resource use and cost, informal care cost, and indirect cost associated with breast cancer in different states of the disease in normal clinical practice. Methods: A retrospective database analysis was used to estimate direct medical resource use and cost, and a patient questionnaire was used to evaluate informal care and work capacity in different states of breast cancer. Results: For patients younger than 65 years of age, the first year after a primary diagnosis total cost amounted to 280,000 SEK ($39,000) and the first year after a local or contralateral recurrence total cost was 351,000 SEK ($48,900). The second and following years after primary breast cancer or recurrence had substantially lower total cost, amounting to 94,000 SEK ($13,000). For patients with metastatic disease, the annual total cost was estimated to 334,000 SEK ($46,500). For patients older than 65 years of age, the total cost for the first year after a primary diagnosis amounted to 80,000 SEK ($11,200) and the total cost for the first year after a local or contralateral recurrence was 92,000 SEK ($12,900). The total cost for the second and following years after primary breast cancer or recurrence was estimated to 18,000 SEK ($2,600), and the total annual cost for patients with metastatic was 122,000 SEK ($17,000). Conclusions: Both direct medical costs and indirect cost vary substantially between disease states. For patients under 65 year of age, indirect costs accounted for more than 50 percent of the total cost.
引用
收藏
页码:223 / 231
页数:9
相关论文
共 15 条
[1]  
Bercez C, 1999, B CANCER, V86, P585
[2]   Cost-effectiveness analysis of breast cancer adjuvant treatment: FEC 50 versus FEC 100 (FASG05 study) [J].
Bonneterre, J ;
Bercez, C ;
Bonneterre, ME ;
Lenne, X ;
Dervaux, B .
ANNALS OF ONCOLOGY, 2005, 16 (06) :915-922
[3]   Short-term effects of breast cancer on labor market attachment: results from a longitudinal study [J].
Bradley, CJ ;
Neumark, D ;
Bednarek, HL ;
Schenk, M .
JOURNAL OF HEALTH ECONOMICS, 2005, 24 (01) :137-160
[4]  
Delea TE, 2006, AM J MANAG CARE, V12, P374
[5]  
Drummond M., 2015, METHODS EC EVALUATIO, V4
[6]   HER-2 testing and trastuzurnab therapy for metastatic breast cancer: A cost-effectiveness analysis [J].
Elkin, EB ;
Weinstein, KC ;
Winer, EP ;
Kuntz, KM ;
Schnitt, SJ ;
Weeks, JC .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :854-863
[7]   COST-OF-ILLNESS METHODOLOGY - A GUIDE TO CURRENT PRACTICES AND PROCEDURES [J].
HODGSON, TA ;
MEINERS, MR .
MILBANK MEMORIAL FUND QUARTERLY-HEALTH AND SOCIETY, 1982, 60 (03) :429-462
[8]  
Johannesson M, 1996, THEORY METHODS EC EV
[9]  
LIDGREN M, 2002, IN PRESS EUR J HLTH
[10]  
*NAT BOARD HLTH WE, 2005, CAUS DEATH 2003